Form 4: Astera Labs Director Sells Shares Under 10b5-1 Plan

Astera Labs Director Jack R. Lazar sold 2,300 shares of common stock on November 20, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Jack R. Lazar of Astera Labs, Inc. (ALAB) sold a total of 2,300 shares of common stock.
• The sales occurred on November 20, 2025, across multiple transactions.
• These transactions were executed automatically pursuant to a Rule 10b5-1 trading plan adopted on May 28, 2025.
• The shares were sold at weighted average prices ranging from $142.3125 to $159.0897 per share.
• Following these transactions, Jack R. Lazar directly beneficially owns 94,851 shares of Astera Labs common stock.

Sentiment

Score: 5

Explanation: Neutral. While insider selling can be perceived negatively, the execution under a pre-established 10b5-1 plan mitigates concerns that the sales are based on new, undisclosed negative information. It's a routine, planned divestment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new, negative information.

Negatives

• A director sold a total of 2,300 shares, which can sometimes be perceived as a negative signal by investors, even if pre-planned.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports insider transactions.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide specific details to analyze broader industry trends or competitive landscape.

Related Party Transactions

• The reported sales of common stock by Director Jack R. Lazar constitute a related party transaction.

Stakeholder Impact

• Shareholders: May interpret insider selling as a negative signal, though the pre-arranged 10b5-1 plan reduces the likelihood of this being based on new, adverse information. The reduction in the director's direct ownership is minor relative to the company's total outstanding shares.

Key Dates

Recommendation

The insider sales by Director Jack R. Lazar are part of a pre-established Rule 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to new, adverse company information. While any insider selling can create a slight overhang, the pre-planned nature mitigates significant negative sentiment. The filing itself does not provide new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Astera Labs, ALAB, Form 4, Insider Trading, Stock Sale, Director, Jack R. Lazar, 10b5-1 Plan, Equity Transaction, Beneficial Ownership